From L-R: Scion Life Sciences co-founders Aaron Kantoff, Tadd Wessel and Samuel Hall

A new VC fund emerges with $310M to cre­ate in­de­pen­dent, com­mer­cial biotechs

A trio of for­mer in­vestors from Or­biMed, Ap­ple Tree Part­ners and Medicxi has come to­geth­er to form a new biotech fund called Scion Life Sci­ences.

Scion has gath­ered $310 mil­lion, about $60 mil­lion over its ini­tial tar­get, to cre­ate six or sev­en new biotech com­pa­nies, Aaron Kantoff, the VC fund’s co-founder and man­ag­ing part­ner, told End­points News in an in­ter­view. They’re fo­cused on qual­i­ty over quan­ti­ty, he said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.